№ files_lp_4_process_2_84832
File format: docx Character count: 3568 File size: 291 KB
Summarizes clinical trial data, patient demographics, treatment outcomes, and RNA sequencing results from the SCOPE1 phase 2/3 trial comparing chemoradiotherapy with or without cetuximab for oesophageal carcinoma.
Year: 2013
Region / City: United Kingdom
Subject: Oncology, Clinical Trial Data
Document Type: Clinical Trial Data Summary
Organization / Institution: Oxford University
Authors: Michael Youdell, Andrew Blake
Target Audience: Researchers and clinicians in oncology
Study Period: Phase 2/3 trial conducted before 2013
Trial Registration: SCOPE1
Data Included: Clinical, demographic, RNA sequencing, treatment outcomes
Treatment Groups: Chemoradiotherapy alone, Chemoradiotherapy plus cetuximab
Patient Population: Non-metastatic oesophageal carcinoma, stage I–III, WHO 0–1
Sample Size: 258 patients
Primary Endpoints: Treatment failure-free proportion at week 24, overall survival
Data Quality Control: MultiQC v1.14, nf-core/rnaseq pipeline
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Supplementary Figures on T Cell Dynamics During Chemoradiotherapy and Nivolumab Treatment
Year: 2026
Study type: Immunology / Oncology
Document type: Supplementary material
Institution: Research laboratory or medical center
Methods: Flow cytometry, 16S rRNA sequencing
Subjects: Tumor-infiltrating lymphocytes and peripheral blood mononuclear cells
Treatment: Chemoradiotherapy followed by nivolumab
Markers analyzed: CD8+, CD4+, Ki-67, CTLA-4
Sample type: Tumor tissue and stool
Period of study: Pre- and post-chemoradiotherapy
Audience: Scientific community
Reflux (GORD) and oesophageal repair: patient symptoms and management guidance
Year: 2026
Region / City: Not specified
Subject: Gastroesophageal reflux and post-surgical oesophageal conditions
Document type: Patient information / medical guidance
Institution: TOFS (Tracheo-Oesophageal Fistula Support)
Author: Not specified
Target audience: Patients with repaired oesophagus or caregivers
Symptoms described: Reflux, vomiting, difficulty feeding, chest pain, coughing, bad breath, dental erosion, hoarse voice, sinusitis, sore throat, ear infections
Medical history: Oesophageal atresia repair, possible silent reflux
Treatment: Medications for reflux, surgery details, feeding and positioning guidance
Additional notes: Recommendation to maintain a personal health log including endoscopy results
Topics: SCOPE1 Chemoradiotherapy Oesophageal